Spots Global Cancer Trial Database for A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Official Title: A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
Study ID: NCT03289962
Study Description
Brief Summary: This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 \[anti-PD-L1\] antibody).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, United States
The Los Angeles Clinic, Los Angeles, California, United States
Stanford Cancer Center, Palo Alto, California, United States
UCSF Comprehensive Cancer Ctr, San Francisco, California, United States
University of Colorado, Aurora, Colorado, United States
Yale University Cancer Center, Smilow Cancer Hospital; Medical Oncology, New Haven, Connecticut, United States
Georgetown University, Washington, District of Columbia, United States
Massachusetts General Hospital., Boston, Massachusetts, United States
Dana Farber Can Ins, Boston, Massachusetts, United States
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States
Columbia University Medical Center; Clinical Research Management Office, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Providence Oncology and Hematology Care Eastside, Portland, Oregon, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Sarah Cannon Res Inst; TN Onc, Nashville, Tennessee, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
UZ Gent, Gent, , Belgium
CHU Sart-Tilman, Liège, , Belgium
Sint Augustinus Wilrijk, Wilrijk, , Belgium
The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada
Princess Margaret Cancer Center, Toronto, Ontario, Canada
Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung, Essen, , Germany
LungenClinic Großhansdorf GmbH; Klinische Forschung, Großhansdorf, , Germany
Nationales Centrum für Tumorerkrankungen Heidelberg (NCT); Thoraxklinik Heidelberg, Heidelberg, , Germany
Fachklinik für Lungenerkrankungen, Immenhausen, , Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, , Germany
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, , Netherlands
LUMC, Leiden, , Netherlands
Universitair Medisch Centrum Utrecht, Utrecht, , Netherlands
Clinica Universitaria de Navarra; Servicio de oncología, Pamplona, Navarra, Spain
Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, , Spain
Karolinska Hospital; Oncology - Radiumhemmet, Stockholm, , Sweden
Akademiska sjukhuset, Onkologkliniken, Uppsala, , Sweden
Barts & London School of Med; Medical Oncology, London, , United Kingdom
Southampton General Hospital; Medical Oncology, Southampton, , United Kingdom
The Royal Marsden Hospital, Sutton, , United Kingdom
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
